patiromer sold brand name veltassa medication used treat high blood taken works binding potassium common side effects include constipation low blood magnesium abdominal approved medical use united states october european union july patiromer used treatment hyperkalemia emergency treatment lifethreatening hyperkalemia acts relatively condition needs kinds treatment example calcium infusions insulin plus glucose infusions salbutamol inhalation typical reasons hyperkalemia chronic kidney disease application drugs inhibit system raas eg ace inhibitors angiotensin ii receptor antagonists potassiumsparing diuretics interfere kidney function general nonsteroidal antiinflammatory drugs patiromer generally well tolerated studies side effects occurred patients included clinical trials mainly gastrointestinal problems constipation diarrhea nausea flatulence also hypomagnesemia low levels magnesium blood patients patiromer binds magnesium gut patiromer tested drugdrug interactions drugs showed binding interaction drugs could reduce availability thus wherefore patiromer received boxed warning us food drug administration fda telling patients wait least six hours taking patiromer oral drugs show interaction vitro selected testing phase studies healthy volunteers assess whether results seen vitro translated effect people studies showed patiromer alter absorption nine drugs coadministered patiromer reduced absorption three drugs coadministered however interaction patiromer three drugs taken hours information submitted fda form supplemental new drug application snda result november fda approved removal boxed warning regarding separation patiromer oral medications updated label recommends patients take patiromer least three hours three hours oral patiromer works binding free potassium ions gastrointestinal tract releasing calcium ions exchange thus lowering amount potassium available absorption bloodstream increasing amount excreted via feces net effect reduction potassium levels blood lowering potassium levels detectable seven hours administration levels continue decrease least hours treatment continued remain stable hours administration last dose potassium levels start rise period least four patiromer absorbed gut metabolized excreted unchanged form substance crosslinked polymer acid divinylbenzenes used form calcium salt ratio sorbitol one molecule per two calcium ions four fluoroacrylic acid units combination called patiromer sorbitex acid odivinylbenzene pdivinylbenzene patiromer sorbitex calcium offwhite light brown amorphous freeflowing powder insoluble water hydrochloric acid heptane phase iii multicenter clinical trial including patients hyperkalemia raas inhibitor treatment participants reached normal serum potassium levels within four weeks subsequent randomization responders group receiving continued patiromer treatment placebo group reoccurrence hyperkalemia versus us fda approved patiromer october approved use european union july httpsenwikipediaorgwikipatiromer